Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04138719 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | recruiting | Phase 2 | 520 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04159142 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer | recruiting | Phase 2 | 414 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 |
| clinicaltrials |
| NCT04759248 | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer(ATREZZO) | active not recruiting | Phase 2 | 55 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05806385 | Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers(LOGIC) | not yet recruiting | Phase 1 / Phase 2 | 36 | Texas Tech University Health Sciences CenterOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 12 | Harbin Medical UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07162298 | Dragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients | recruiting | Phase 2 | 72 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07040644 | A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC | not yet recruiting | Phase 2 | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07153965 | Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05900206 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer(ARIADNE) | recruiting | Phase 2 | 370 | Karolinska University HospitalOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07129187 | SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response | not yet recruiting | Phase 2 | 30 | Chuan WangOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07136974 | Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. | not yet recruiting | Phase 2 | 280 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06599216 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer | active not recruiting | Phase 2 | 30 | Harbin Medical UniversityOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07134153 | Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases(INOVATE) | recruiting | Phase 1 / Phase 2 | 139 | Fudan UniversityOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06198751 | A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | active not recruiting | Phase 2 | 104 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07107217 | Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer(Camella) | not yet recruiting | Phase 2 | 40 | Blokhin's Russian Cancer Research CenterOTHER | 0 | Aug 17, 2025 | clinicaltrials |
| NCT07125950 | SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07116824 | HB1801 Combined Treatment of HER2-positive Breast Cancer | not yet recruiting | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 12, 2025 | clinicaltrials |
| NCT03740893 | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer(PHOENIX) | recruiting | Phase 2 | 119 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07113613 | Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy | recruiting | Phase 2 | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07108309 | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer(AREAL) | recruiting | Phase 2 | 124 | BiocadINDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT06973525 | This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.(HER2-DM-NACT) | not yet recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07007780 | Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC | not yet recruiting | Phase 2 | 35 | Xijing HospitalOTHER | 0 | Jul 29, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05181033 | Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor | recruiting | Phase 2 | 120 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06224244 | External Hypofractionated Radiotherapy With Simultaneous Integrated Boost in Early Breast Cancer Patients(ESIBIRE) | active not recruiting | Phase 2 | 180 | Regina Elena Cancer InstituteOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07083505 | A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT07067307 | Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT02436993 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | active not recruiting | Phase 2 | 120 | University of California, IrvineOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04083963 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | active not recruiting | Phase 2 | 13 | University of Illinois at ChicagoOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06402435 | SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer | recruiting | Phase 2 | 50 | Hubei Cancer HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047443 | SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression | not yet recruiting | Phase 2 | 18 | Anhui Provincial Cancer HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047755 | Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC | not yet recruiting | Phase 2 | 48 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 2, 2025 | clinicaltrials |
| NCT07041437 | Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03831178 | Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting(DHA-WIN) | active not recruiting | Phase 2 | 76 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06500208 | Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06665178 | Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer | recruiting | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06394661 | Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer | active not recruiting | Phase 2 | 109 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 23, 2025 | clinicaltrials |
| NCT06568692 | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | recruiting | Phase 2 | 90 | Processa PharmaceuticalsINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06150898 | Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)(KePreSt) | recruiting | Phase 2 | 112 | Jules Bordet InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07019337 | Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | not yet recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07014410 | Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer | recruiting | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02788981 | Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 29 | University of ChicagoOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07011823 | Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC(KEY-MELT) | not yet recruiting | Phase 2 | 20 | Gangnam Severance HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 11, 2025source: clinicaltrials